Cytokinetics Inc (CYTK)
Cytokinetics develops medicines that act on muscle function, starting with MYQORZO for obstructive hypertrophic cardiomyopathy, a serious heart disease. It last closed at $51.65 on Nov 17, down 2.86% on the day. CYTK last reported earnings on Thu, Aug 6, 2026. The average 12-month price target from 4 analysts is $102.00 (+97.5% from the last close), with a high of $113.00 and a low of $90.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 4 whale options trades in CYTK, 75% of them bullish and 25% bearish. In the past 30 days there were 2 dark pool prints totaling $2.2M, the largest $1.4M.
Key Stats
Last 12 monthsNot reported for this period.
From CYTK's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on CYTK in the past 90 days. The average target is $102.00, with a high of $113.00 and a low of $90.00, compared with the last close of $51.65.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 5 | Citigroup | Target raised | Buy | $99 → $105 |
| Nov 5 | Leerink Partners | Maintained | Buy | $100 |
| Oct 8 | RBC Capital | Target raised | Buy | $112 → $113 |
| Sep 25 | HC Wainwright & Co. | Target lowered | Buy | $140 → $90 |
| Aug 31 | HC Wainwright & Co. | Reiterated | Buy | $140 |
Technical Analysis
The stock is 14% below its 20 day and 22% below its 50 day average. It is 35% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the 52 week low at $51.38, and the nearest resistance the Pivot at $51.97.
| RSI (14) | 30.71 | Weak, oversold below 30 | Neutral |
| MACD | -2.81 | Below its signal line | Bearish |
| Stochastic | 9.5 | Near the bottom of its range | Oversold |
| ADX (14) | 27.7 | Trending down | |
| Williams %R | -98.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -140.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −17.1% | Change over 10 sessions | Bearish |
| ATR (14) | $2.67 | Typical daily range, 5.2% of price |
| RSI (14) | 31.47 | Weak, oversold below 30 | Neutral |
| MACD | -4.21 | Below its signal line | Bearish |
| Stochastic | 3.7 | Near the bottom of its range | Oversold |
| ADX (14) | 24.6 | Weak trend | |
| Williams %R | -99.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -142.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −30.0% | Change over 10 sessions | Bearish |
| ATR (14) | $5.83 | Typical daily range, 11.3% of price |
What happened before
See how CYTK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CYTK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in CYTK in the last 90 days.
Dark Pool
30DCYTK Institutional Ownership
Full report →- ▲267 buying vs 200 selling
- ▲Held by funds +12.8 pts
- ▼Funds holding -18
- ▼Superinvestors: 1 added, 2 cut
- ▲Put/call 0.08 to 0.06
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 469 | 487 | −3.7% |
| In funds' top 10 | 13 | 15 | −13.3% |
| Held by funds | 128.1% | 115.3% | +12.8 pts |
| New / increased | 61 / 206 | 91 / 237 | −18.6% |
| Reduced / sold out | 127 / 73 | 102 / 50 | +31.6% |
| Put/call ratio | 0.06 | 0.08 | −18.5% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CYTK is in one of them and how their past CYTK trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CYTK in an article yet. Here's the latest on the wider market.
CYTK Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Sep 29, 2026 | Oct 12, 2026 | 13 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Jun 30, 2026 | Jul 2, 2026 | 2 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Oct 9, 2025 | Nov 18, 2025 | 40 d |
| Lisa McClainR · MI | Sell | $1K – $15K | Jun 17, 2025 | Aug 13, 2025 | 57 d |
| Lisa McClainR · MI | Buy | $1K – $15K | Jun 11, 2025 | Aug 13, 2025 | 63 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Cytokinetics
Cytokinetics is a biopharmaceutical company based in South San Francisco, California, that develops medicines aimed at muscle function. Its first approved product is MYQORZO, a tablet for adults with obstructive hypertrophic cardiomyopathy, a serious heart disease. The company sells its medicines to patients and to prescribing cardiologists, and it is working on other drug candidates for heart and neuromuscular diseases.
- Headquarters
- South San Francisco, CA
- Founded
- 1997
- Website
- cytokinetics.com ↗




